

Patient alert card



Please show this information to all emergency and healthcare providers.
In patients who require blood transfusion, irradiation of cellular blood components is recommended prior to administration to prevent transfusion-related graft-versus-host disease. Consultation with a hematologist is advised.

Name: _____

MAVENCLAD® started on (DD/MM/YYYY) _____ / _____ / _____

This patient is being treated with MAVENCLAD (cladribine tablets), a medication used to treat relapsing-remitting multiple sclerosis (RRMS) in adults.

If you are required to treat this patient for a **serious infection**, or any other conditions you feel may be associated with their MAVENCLAD treatment, please inform the prescribing neurologist listed inside this card.



FOR MORE INFORMATION, THE FULL PRODUCT MONOGRAPH IS AVAILABLE AT MAVENCLAD.CA

Fold

My MAVENCLAD treatment team

Fill in the contact details of your healthcare team below.

Neurologist

Name _____

Phone _____

Family doctor

Name _____

Phone _____

Clinic nurse

Name _____

Phone _____

Fold

adveva™ - patient support program for MAVENCLAD

1-888-677-3243 Available 24/7 (Nurse available 8:00 AM-8:00 PM EST)

Fold

© 2020 EMD Serono. All rights reserved.
MAVENCLAD® is a registered trademark of Merck KGaA, Darmstadt, Germany.

adveva™ is a trademark of Merck KGaA, Darmstadt, Germany.

Importer & Distributor:
EMD Serono, A Division of EMD Inc., Canada
A business of Merck KGaA, Darmstadt, Germany
2695 North Sheridan Way, Suite 200
Mississauga, Ontario L5K 2N6 Canada
www.emdserono.ca

adveva: 1-888-677-3243



CA/CLA/0318/001511E

